INS and type 2 diabetes mellitus: Antioxidants act at an earlier stage of T2D pathogenesis than traditional insulinotropic agents, insulin sensitisers, and sodium-glucose cotransport protein 2 inhibitors and can serve as a new strategy for T2D treatment, with associated mitochondria-targeted antioxidant drugs showing good tolerability.